SHWZ Overview

Acquisition Announcement: Vireo Growth Inc. plans to acquire approximately $2.6 million in senior secured convertible notes from Medicine Man Technologies (Schwazze) for about $1.6 million in subordinate voting shares, representing a significant discount.

Transaction Details: Upon completion, Vireo will hold around 89% of Schwazze's outstanding notes, with the transaction subject to customary conditions and regulatory approvals.

Company Overview: Vireo, founded in 2014, focuses on the medical cannabis industry, emphasizing a disciplined and strategic approach to market operations and growth.

Forward-Looking Statements: The press release includes forward-looking information regarding financial outlooks and potential risks, cautioning readers against placing undue reliance on these projections.

Market Performance Overview: The cannabis industry in key U.S. markets shows mixed results, with California leading in tax revenue while Massachusetts and New Mexico experience slight declines in sales; Massachusetts saw a 1% decrease in November sales compared to October, and New Mexico's sales fell by 2% from the previous month.

California's Tax Revenue: California generated $250.5 million in cannabis tax revenue for Q3 2024, contributing over $6.5 billion since 2018, despite the elimination of the cultivation tax in July 2022, indicating the market's ongoing financial significance.

Schwazze's Financial Restatement: Colorado-based cannabis company Schwazze announced it will restate its financial statements for FY 2022/23 and Q1-Q3 2023 due to accounting errors related to preferred shares, operating leases, and inventory valuations, although key metrics like revenue remain unaffected.

Historical Accounting Blunders: The article highlights infamous accounting mistakes in history, including significant errors by Fannie Mae and Freddie Mac in 2003, JPMorgan Chase's $6 billion loss in 2012, and Knight Capital Group's $440 million trading glitch, emphasizing the potential consequences of minor accounting errors.

Preliminary Financial Results: Schwazze reported approximately $42 million in revenue for Q3 2024, down from $46.75 million the previous year, with adjusted EBITDA of about $11 million and cash flow from operations of $200,000.

Delayed Filing Update: The company is experiencing delays in filing its quarterly report due to a transition to a new auditor, Baker Tilly US, LLP, which requires additional time to complete reviews of prior financial statements following issues with the previous accountant.

Colorado Cannabis Sales: In Colorado, cannabis sales reached $122 million in August, showing a 5% increase in quarter-to-date sales compared to earlier months, despite an overall year-over-year decline in revenue per dispensary.

Connecticut Cannabis Sales: Connecticut's cannabis sales totaled $23.4 million in September, reflecting a 9% month-over-month decrease and a 7% drop from the previous year, with average revenue per dispensary also declining significantly.

Impact of 280E Removal: The potential removal of Section 280E in 2025 could significantly improve the financial health of multi-state cannabis operators (MSOs) by allowing them to deduct normal business expenses, leading to increased cash flow and profitability.

Financial Outlook for MSOs: An analysis indicates that while several major MSOs are projected to manage their fixed charges in 2025, challenges may arise in 2026 due to debt maturities and uncertain tax liabilities, particularly for companies like Curaleaf and Trulieve.